Patients will receive treatment with GX-I7 at a pre-determined dose (Level I) on Day1 of each cycle.

Patients will receive treatment with GX-I7 at a pre-determined dose (Level II) on Day1 of each cycle.

Patients will receive treatment with GX-I7 at a pre-determined dose (Level III) on Day1 of each cycle.

Patients will receive treatment with GX-I7 at a pre-determined dose (Level IV) on Day1 of each cycle.

Optimal fixed dose of GX-I7 from Dose-escalation stage on Day1 of each cycle (Maximum tolerable dose or Maximum efficacious dose or Maximum administered dose level or consecutive lower or upper dose level which does not exceed Maximum tolerable dose based on Safety Monitoring Committee(SMC) decision)

During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.

Incidence and nature of DLT(Dose-Limiting Toxicity)s

Incidence, nature and severity of adverse events graded according to NCI CTCAE v4.0

Changes of ALC(Absolute lymphocyte count) from the baseline

Objective response(OS) defined as the time from the date of diagnosis to the death from any cause